Psoriasis and Psoriatic Disorders Clinical Trials

A listing of Psoriasis and Psoriatic Disorders medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Arizona

Arizona Arthritis & Rheumatology Research, PLLC
Glendale Arizona 85304

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

California

Dermatology Research Associates
Los Angeles California 90045

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Dermatology Specialists, Inc.
Oceanside California 92056

A national, multi-center, randomized, double-blind, 4 arm, 8 week study in subjects with psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs)

Dermatology Specialists, Inc.
Oceanside California 92056

A Phase 3, Multi-site, randomized, mixed-blind, parallel-group treatment withdrawl and re-treatment study of the efficacy and safety of 2 oral doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Dermatology Specialists, Inc.
Oceanside California 92056

You may be interested in learning about a clinical research study of an investigational study medication for symptoms associated with plaque psoriasis

Stanford University School of Medicine
Palo Alto California 94304

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Colorado

AboutSkin Research
Englewood Colorado 80113

A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Connecticut

New England Research Associates, LLC
Trumbull Connecticut 06611

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Florida

Rheumatology Associates of Central Florida, PA
Orlando Florida 32806

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Millennium Research
Ormond Beach Florida 32174

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Arthritis Center, Inc.
Palm Harbor Florida 34684

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Integral Rheumatology & Immunology Specialists (IRIS)
Plantation Florida 33324

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

University of South Florida - Morsani Center for Advance Healthcare
Tampa Florida 33612

A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 17 years of age) with mild to moderate plaque psoriasis

University of South Florida - Morsani Center for Advance Healthcare
Tampa Florida 33612

Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis

Georgia

Columbus Regional Research Institute
Columbus Georgia 31904

Considering potential research options for managing psoriasis?

Illinois

Northwestern University
Chicago Illinois 60611

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Louisiana

Tulane University
New Orleans Louisiana 70112

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Maryland

The Center For Rheumatology And Bone Research
Wheaton Maryland 20902

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Massachusetts

ActivMed Practices & Research, Inc.
Beverly Massachusetts 01915

Moderate to Severe Plaque Psoriasis study

Tufts Medical Center
Boston Massachusetts 02111

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Brigham & Women's Hospital
Boston Massachusetts 02115

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Clinical Pharmacology Study Group
Worcester Massachusetts 01605

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Michigan

University of Michigan
Ann Arbor Michigan 48109

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Minnesota

St. Paul Rheumatology, PA
Eagan Minnesota 55121

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Missouri

MediSearch Clinical Trials
St. Joseph Missouri 64506

A 30-day study evaluating a topical corticosteroid spray.

Clayton Medical Research
St. Louis Missouri 63117

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Nebraska

Physician Research Collaboration, LLC
Lincoln Nebraska 68516

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

New Hampshire

ActivMed Practices & Research, Inc. NH
Newington New Hampshire 03801

Are you suffering from moderate to severe plaque psoriasis?

New York

NEW

Sadick Research Group
New York New York 10075

A multi-center, double blind, randomized, vehicle-controlled study to evaluate the safety and efficacy of a topical lotion in the treatment of moderate to severe psoriasis.

NEW

Sadick Research Group
New York New York 10075

A multi-center, open label study to evaluate the long term safety of a topical lotion for the treatment of plaque psoriasis.

Sadick Research Group
New York New York 10075

A Phase 3, Multicenter, Double-blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the treatment of Plaque Psoriasis

Sadick Research Group
New York New York 10075

A Research Study for Patients with Moderate Psoriasis

The Rockefeller University Hospital
New York New York 10065

Comparative analysis of small and large plaque psoriasis

Rockefeller University
New York New York 10065

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

North Carolina

PMG Research of Cary
Cary North Carolina 27518

Moderate to Severe Chronic Plaque Psoriasis

High Point Clinical Trials Center
High Point North Carolina 27265

Moderate to Severe Plaque Psoriasis Research Study

Wake Forest University - Department of Dermatology
Winston-Salem North Carolina 27104

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Ohio

Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati Ohio 45219

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Case Western Reserve University - University Hospitals Case Medical Center, Department of Dermatology
Cleveland Ohio 44106

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Pennsylvania

East Penn Rheumatology Associates, P.C.
Bethlehem Pennsylvania 18015

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Rhode Island

Clinical Partners, LLC
Johnston Rhode Island 02919

Opportunity to participate: New Psoriasis Study Being Conducted

Tennessee

PMG Research of Bristol
Bristol Tennessee 37620

Moderate to Severe Chronic Plaque Psoriasis

West Tennessee Research Institute
Jackson Tennessee 38305

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Texas

Metroplex Clinical Research Center
Dallas Texas 75231

A phase 2, open-label, dose-finding study to evaluate the safety, tolerability, and activity of KD025 in subjects with Psoriasis Vulgaris who failed first-line therapy.

Research Across America
Dallas Texas

Pediatric Psoriasis Research Study